Novel Treatment Advances and Approaches in the Management of Hepatocellular Carcinoma (HCC): Expert Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Eisai

Description:
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. Liver cancer is still on the rise and death rates are increasing faster than any other type of cancer. Prognosis is especially poor for those with unresectable HCC. Fortunately for patients with HCC, new agents have recently been approved that provide new options for clinicians in the first-line setting. For the treatment of HCC, transplantation is an option for patients, but there is a limited supply of good-quality donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible, in unresectable HCC. Fortunately, new options are on the cusp of becoming available in the first-line setting for the first time in 10 years. These options include targeted therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs). In addition to newly approved therapies, combination therapy in the second line setting is also changing the treatment paradigm..

Upon completion of this activity, participants will be able to:

  • Characterize the direct and indirect costs of hepatocellular carcinoma (HCC) diagnosis, care and management, and implications for healthcare resources

  • Compare and contrast the mechanisms of action, safety and efficacy of new and emerging targeted agents in the treatment of advanced and/or unresectable HCC, both in first-line therapy and beyond

  • Assess the relative benefits and limitations of immunotherapies for HCC beyond first-line therapy

  • Identify patients with advanced HCC for whom a targeted agent or immunotherapy is an appropriate choice for the next step in the management of their cancer

  • Analyze effective strategies to monitor and manage the unique adverse events associated with new and emerging therapies in advanced HCC
     

Faculty: Renuka Iyer, MD
Associate Professor of Oncology
Co-Director, Liver and Pancreas Tumor Center
Section Chief for Gastrointestinal Oncology
Roswell Park Cancer Institute

Disclosure:

Dr. Iyer serves as a consultant for Bayer, Eisai, Lexicon, Merck, and Novartis. She has received grant/research support from Merck and Ipsen. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Eisai

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue